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Abstract CFS, a recently named heterogeneous disorder, is an 
illness of unknown etiology. The association of CFS with viral 
infections has been suggested. A common association between 
CFS and several viruses examined has not been confirmed. Here, 
we centered on the possible link between CFS and BDV infection. 
By nested RT-PCR followed by hybridization, BDV RNA was 
demonstrated as a clear signal in PBMCs in 3 out of 25 CFS 
patients. The amplified cDNA fragments were cloned and se- 
quenced. A total of 16 clones were studied. Intra-patients diver- 
gencies of the p24 were 2-9%, 3--20%, and 3-11% in the deduced 
amino acids. Inter-patient divergencies among the 16 clones were 
3-24%. Antibodies to recombinant BDV p24 protein were de- 
tected in 6 CFS patients including one carrying BDV RNA. 
Overall, these gave the prevalence of 32% (8/25) in Japanese CFS 
patients, suggesting that Japanese CFS is highly associated with 
active infection of BDV, or a related agent. 
Key words'. Borna disease virus; Chronic fatigue syndrome; 
Peripheral blood mononuclear cell; RT-PCR 
1. Introduction 
Viral infections have been widely implicated in the etiology 
of a variety of neurological nd neuropsychiatric syndromes [ 1]. 
The majority of the studies have focused on herpesviruses, 
especially herpes simplex virus type 1, cytomegalovirus and 
Epstein-Barr virus. However, the studies have yielded varied 
results in the levels of viral antibodies, viral antigens and viral 
genomes [1]. 
CFS is an illness which begins with an acute influenza-like 
symptoms including feverishness, headache, recurrent tender 
lymph glands, sore throat, diffuse muscle and joint pain [2]. 
Debilitating fatigue or easy fatiguability, and neuropsychologic 
problems uch as difficulties with concentration a d depression 
are other symptoms [2]. The Center for Disease Control pro- 
posed a working case definition for this syndrome, which relies 
on clinical and laboratory criteria [3]. CFS, also known as 
*Corresponding author. Fax: (81) (11) 707-6837. 
Abbreviations." CFS, chronic fatigue syndrome; BDV, Borna disease 
virus; RT-PCR, reverse transcriptase-polymerase chain reaction; 
PBMC, peripheral blood mononuclear cell; GST, glutathione S-trans- 
ferase. 
myalgic encephalomyelitis or postviral fatigue syndrome, has 
been strongly suggested to be sequelae of viral infections. The 
association with EB virus, human herpesvirus-6, coxsackie 13 
virus, and HTLV-1I has been examined in this syndrome [4]. 
However, a common association between CFS and a certain 
agent has not been found. 
BDV is a neurotropic, yet unclassified, nonsegmented, nega- 
tive-sense, single-stranded RNA virus which naturally infects 
horses and sheep [5,6]. In addition, BDV, or a related agent, 
has been suggested tobe closely associated with specific psychi- 
atric disorders, especially major depression, in humans mainly 
by using conventional serological assays uch as immunofluo- 
rescence [7,8], although ealthy people also have a low preva- 
lence of anti-BDV antibodies [9-11]. Recently, a nested RT- 
PCR using primers for the BDV p24 gene has been developed 
to detect he genetic footprints of BDV in PBMCs derived from 
psychiatric patients [12,13]. As high as 36.7% (22160) examined 
showed positive reaction in psychiatric patients in our examina- 
tion [12], while the same technique showed only (4.7%) 8/172 
prevalence in PBMCs derived from healthy blood donors [14]. 
The phosphorylated p24 protein is encoded in the second open 
reading frame and it may correspond to the polymerase cofac- 
tor found in other nonsegmented, negative-stranded RNA vi- 
ruses [5]. In this report, we examined a possible link of CFS 
with BDV infection, because depression is similarly observed 
in CFS patients as one of the clinical markers for CFS [2]. 
2. Materials and methods 
2.1. Patients 
We studied BDV seroprevalence in randomly selected 25 Japanese 
CFS patients (Table 1), who were diagnosed with CFS in accordance 
with the guidelines established by the Center for Disease Control [3]. 
2.2. BDV and cells" 
MDCK cells uninfected or persistently infected with BDV (MDCK/ 
BDV) [15] were used as controls. 
2.3. Detection of BDV RNA in PBMCs 
Total RNA fractions were extracted from whole EDTA-treated 
blood by using an RNA extraction kit (Isogen, Nippon Gene Co., 
Tokyo, Japan). To detect BDV-specific RNA, the extracted RNA was 
amplified by nested RT-PCR, under the same conditions as described 
[12], to obtain a fragment of the p24 coding region which is relatively 
conserved within the BDV genome [16]. Briefly, one microgram of 
cellular RNA was amplified by nested RT-PCR using two sets of 
primers as follows: for the 1st PCR, at nucleotides 1387-1405 and at 
nucleotides 1865 1847 and for 2nd PCR, at nucleotides 1443-1461 and 
at nucleotides 1834-1816. RT-PCR consisting of reverse transcription 
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Fig. 1. Nested RT-PCR for the detection of BDV RNA in PBMCs from patients with CFS. A total of 25 samples (lanes 1-25) from CFS patients 
were subjected to nested RT-PCR. The products of PCR amplification of the BDV p24 region were resolved by agarose gel electrophoresis, then 
stained with ethidium bromide (A). The results of the Southern blot hybridization using four oligomers as probes are also shown (B). The positive 
and negative controls were the RNA fractions from MDCK/BDV (+) and MDCK (-), respectively. MW indicates the size markers (Ox174 
DNA/HaeIII fragments). 
and amplification of the viral cDNA, was performed according to the 
protocol described for the EZ rTth RNA PCR kit (Perkin-Elmer Corp., 
Branchburg, NJ, USA). The final products were separated by 1.5% 
agarose gel electrophoresis, blotted onto a nylon membrane, then 
Southern hybridized using four 3zp-labeled synthetic oligonucleotides, 
sense nucleotides 1462-1485, 1485-1507 and 1637-1658, and the antis- 
ense nucleotide 1811-1791. Each of the PCR products were cloned into 
the pCRTMII plasmid vector (Invitrogen Corp., San Diego, CA). Each 
clone was sequenced by use of the Dye Primer Cycle Sequencing Kit 
(Applied Biosystems Inc., Foster City, CA, USA) in a 373A DNA 
Sequencer. Nucleotide numbers and the deduced amino acid sequences 
were those, previously reported for the He/80 strain of BDV [17]. 
2.4. Detection of anti-BDV antibodies 
Anti-BDV antibodies in the plasma obtained from the same EDTA- 
treated blood as for RNA preparations were examined by immunoblot- 
ting, as described [14]. BDV antigen for these assays was horse BDV- 
derived recombinant full-length p24 fusion protein with GST and a 
negative control antigen was GST alone. Both GST-p24 and (3ST 
proteins were used after purification by glutathione Sepharose 4B 
(Pharmacia Biotech AB, Uppsala, Sweden) column chromatography. 
The molecular weight values of the proteins in immunoblotting were 
calculated by comparing their mobilities with those of marker proteins 
in a calibration kit (Bio-Rad). 
3. Results 
3.1. BD V RNA in PBMCs derived from CFS patients 
A total of 25 CFS Japanese patients (Table 1) were examined 
for BDV RNA in their PBMCs. Nested RT-PCR revealed the 
presence of BDV RNA in CFS patients (Fig. 1). The amplified 
products derived from patients #14, #21 and #25 showed spe- 
cific strong signals with 374 bp, which corresponds to the size 
of the fragment from persistent BDV in MDCK cells, by both 
ethidium bromide staining and Southern blotting. The ampli- 
fied products derived from patients #13 and #18 showed only 
faint signals with 374 bp by Southern blotting. On the other 
hand, the sample from patient #10 showed a band with a 
slightly higher mobility which was apparently stained with 
ethidium bromide but was negative by Southern blotting with 
synthetic oligonucleotides u ed. These results are summarized 
in Table 1. 
The amplified cDNA fragments from 3 patients were cloned, 
sequenced and analyzed. Six or four cDNA clones were derived 
from each patient, i.e. p14-1, -9, -10, -11, -22 and -25 from 
Fig. 2. Nucleotide and deduced amino acid sequences of BDV p24 region in PBMCs derived from 3 CFS patients. Sequence results of 16 cDNA 
clones, 6 from patient #14 (p14-1 to -25), 4 from patient #21 (p21-3 to -22), and 6 from patient #25 (p25-3 to -19), at nucleotides 1473 1772 are 
comparatively shown with those of horse-derived BDV, He/80 [17], strain V [16] and WT-1 [16] (A). Nucleotide sequences identical with those of 
He/80 were indicated by dots. Dashed lines indicate deleted nucleotides. The deduced amino acids according to these sequences were also similarly 
shown (B). 'X' indicates amino acid residue which is not determined because of the presence of nucleotide deletion within a corresponding codon. 
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Fig. 3. Anti-BDV antibodies in the plasma samples from patients with CFS. The purified GST-BDV p24 (51 kDa) and GST as a control were similarly 
resolved by SDS-PAGE followed by its blotting onto a nitrocellulose membrane for immunoblotting. Hundred-fold ilutions of the plasma samples 
derived from 25 CFS patients were used. The results of 6 patients (#7, #11, #13, #14, #16, and #17) positive for anti-BDV and of 2 patients (#21 
and #25) negative for anti-BDV were shown as representatives. 
patient # 14; p21-3, -4, - 11, and -22 from patient #21; and p25-3, 
-4, -7, -13, -18 and -19 from patient #25. Fig. 2A shows the 
nucleotide sequence for each of the 16 p24 cDNA clones. Fig. 
2B shows the amino acid residues deduced from the nucleotide 
sequence of each clone. The results showed that the CFS-de- 
rived BDV sequences were similar to, but significantly different 
from, the reported sequences of horse-derived BDV, He/80 [17], 
strain V [16] and WT-1 [16] which were also shown in Fig. 2 
as controls. The two base deletion, GG in place of GGGG at 
nt 1552-1555, was detected in all cDNA clones from patient 
#25. Hence, all these cDNA clones were defective for p24. The 
same deletion was also detected in 3 among 4 clones from 
patient #21. In addition, there were several amino acid substi- 
tutions specific to the patients. Especially, substitutions to the 
same amino acids at several sites were observed in the clones 
derived from patients #21 and #25. Computer  analyses (GEN-  
ETYX-MAC,  Software Development Co. Ltd., Tokyo, Japan) 
revealed that intra-patient divergencies in this p24 region at the 
amino acid level were 2-9% (#14 patient), 4-20% (#21 patient), 
and 3 11% (#25 patient). Inter-patient divergencies were 9-  21% 
between patients #14 and #21, 13-22% between patients #14 
and #25, and 3-24% between patients #21 and #25, which were 
higher than the divergencies from those of the horse strain V, 
He/80 and WT-1 by 6-10% (patient #14), 8-12% (patient #21), 
and 8-14% (patient #25). Thus, in p24, BDV in the PBMCs in 
CFS patients undergoes mutat ion at high rates in vivo. 
3.2. Detection of anti-BD V antibodies in plasma 
Hundred-fold i lutions of 25 plasma samples obtained from 
the same blood as used for RNA preparations were examined 
for the presence of ant i -BDV antibodies by immunoblott ing.  
The plasma from 6 patients (patients #7, #11, #13, #14, #16 
and #17) including patient #14 who showed a positive reaction 
for BDV RNA were positive by immunoblot  analysis using 
GST-p24, but not GST alone (Fig. 3). In the plasma from 
patients #21 and #25 showing positive signals for BDV RNA 
in their PBMCs,  no specific reaction by immunoblott ing was 
observed (Fig. 3). These results are summarized in Table 1. 
4. Discussion 
Our findings suggest hat Japanese CFS is associated, at least 
in part, with active infection of BDV, or BDV-related agent, 
a l though no serologic evidence of BDV infection was reported 
in CFS patients by a German group [18]. This discrepancy 
seems to be due to the different echniques, namely they used 
immunofluorescence assay, while we used RT-PCR to detect 
BDV-related RNA in PBMCs, and immunoblot  using purified 
BDV p24 recombinant protein to detect ant i -BDV ant ibody in 
plasma. 
BDV RNA was not always detected in the PBMCs in the 
same CFS patients positive for ant i -BDV antibodies (Table 1). 
Essentially similar results were also observed in patients with 
psychiatric disorders [12,13], blood donors [14], healthy horses 
[19] and cats [20]. These observations suggest hat the group 
positive for ant i -BDV antibodies and negative for BDV RNA 
in PBMCs had been exposed to BDV antigens. Alternatively, 
the BDV in this group might be present in the tissue cells other 
Table 1 
Profiles of 25 CFS patients and their summarized results for BDV 
Patient Age Sex Disease BDV Anti-BDV 
onset RNA p24 
1 19 M 1990.7 - - 
2 23 M 1991.5 - - 
3 24 M 1994.4 - - 
4 24 M 1988.12 - - 
5 25 M 1991.12 - - 
6 26 M 1994.9 - - 
7 32 M 1990.7 - + 
8 36 M 1994.1 - - 
9 36 M Around 1988 - - 
10 37 M 1993.10 - - 
11 40 M Around 1985 - + 
12 40 M 1989.1 - - 
13 43 M 1991.9 - + 
14 44 M 1992.3 + + 
15 57 M 1990.2 - - 
16 21 F 1991.6 - + 
17 21 F 1995.1 - + 
18 22 F 1991.12 - - 
19 25 F 1991.1 - - 
20 25 F 1994.3 - - 
21 28 F 1991.8 + - 
22 30 F 1993.2 - - 
23 35 F 1991.5 - - 
24 36 F 1991.4 - - 
25 52 F 1990.4 + - 
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than PBMCs, because we examined BDV RNA only in 
PBMCs. In contrast, the group positive for BDV RNA in 
PBMCs and negative for anti-BDV antibodies eems to be 
latently infected with BDV, as indicated by 2 base deletions in 
all 6 p24 cDNA clones from patient #25 and 3 among 4 p24 
cDNA clones from patient #21 (Table 1, Fig. 2). Alternatively, 
disruption of viral latency might give rise to high expression of 
viral proteins which complexed with the circulating anti-BDV 
antibodies, and interfered with immunoblot analysis. Overall, 
8 among 25 (32%) CFS patients examined showed the associa- 
tion of BDV (Table 1). One patient amplified a smaller frag- 
ment under the same PCR conditions, but this did not hybridize 
with the p24-specific probe, suggesting that Southern blotting 
is a necessary step to avoid false positive results. It is notewor- 
thy that a strong association of BDV was demonstrated with 
patients with major depression [7,8], because similar depression 
is also observed in patients with CFS [2]. The association of 
BDV with 32% CFS patients might be due to the immunocom- 
promized state of their patients which is a clinical marker of 
CFS [21], or may indicate a relation with the disease at least in 
part in the Japanese patients. An extensive follow-up study 
from the onset of the disease on BDV RNA in PBMCs and 
anti-BDV antibodies, as done in psychiatric patients [13], will 
determine the prevalence of BDV infection in this syndrome 
and may clarify whether this agent is related with the disease 
pathogenesis or the results of reactivation of latent BDV by an 
unknown stimulation mechanism. 
The amplified products of the p24 gene in PBMCs from three 
patients with CFS were cloned and sequenced. Schneider et al. 
[16] compared the sequence of the p24 among several BDV 
strains from horses. They found a 3.1% variation at the nucle- 
otide level and a 1.5% difference at the amino acid level. Binz 
et al. [22] also found that the p24 in tissues from 4 infected 
horses had a maximum divergence of 3.3% at the nucleotide 
level, and 1.5% at the amino acid level. In this study, the intra- 
and inter-patient sequence variabilities of the p24 were much 
higher even at the deduced amino acid level (Fig. 2). Our recent 
analyses of the p24 from 3 psychiatric patients have also re- 
vealed slightly more sequence variabilities, i.e. 7.7-14.5%, 10.3- 
17.1% and 6.0-16.2% in intra-patient divergencies and 12.8- 
28.2% in inter-patient divergencies at the amino acid level [23]. 
The reason for the higher variabilities detected in these studies 
is unknown, but could have resulted from the following rea- 
sons, i.e. (1) higher number of clones analyzed in this study; and 
(2) difference of mutation rates in human and horse cells. In 
addition, there is also a possibility that the mutations observed 
here were PCR artifacts. However, misreading or template 
switching by the Taq polymerase would be a random event. 
Therefore, it would not have caused mutations at a limited 
number of nucleotide positions in all of 4 or 6 eDNA clones 
from one patient (Fig. 2). Although the frequency of BDV 
polymerase rror is unknown, it may be as high as rhabdo- 
viruses, i.e. 10 -4 to 4 X 10 -4 substitutions per base incorporated 
at a single site [24]. These variations suggest hat BDV in 
PBMCs is subjected to higher selective pressure in vivo, espe- 
cially those immunologic in nature. In addition, high capacity 
for variability may allow this virus to respond to the influence 
of host factors, such as the age, immune status or genetic 
background of the host, which would affect on the pathogenesis 
of BDV, as already discussed previously [25]. This possibility 
may be supported by our recent finding of the outbreak (2 
developing CFS and another 2 showing related symptoms in 
the 5 members) in the family of the patient #14, in which 3 of 
the 5 members had significantly higher antibodies to BDV (not 
shown). The BDV genome characterization i  each family 
member may reveal the cause of transmission and pathogen- 
icity of the particular BDV in patient #14. 
Since we characterized only about 3% of the genome in this 
study, a comparison of the whole genomes would be required 
to determine the similarity and dissimilarity of the BDV in CFS 
patients with those in horse or psychiatric patients. 
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